logo
Twitter
Discord
Email
logo
Balchem Corporation

Balchem Corporation

NASDAQ•BCPC
CEO: Mr. Theodore L. Harris
Sector: Basic Materials
Industry: Chemicals - Specialty
Listing Date: 1986-06-03
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
Contact Information
5 Paragon Drive, Montvale, NJ, 07645, United States
845-326-5600
www.balchem.com
Market Cap
$5.07B
P/E (TTM)
34.3
28.2
Dividend Yield
0.6%
52W High
$177.40
52W Low
$139.17
52W Range
46%
Rank23Top 6.9%
6.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$267.56M+11.51%
4-Quarter Trend

EPS

$1.25+20.19%
4-Quarter Trend

FCF

$50.67M+20.20%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Sales Growth Strong Nine months net sales reached $773.544M, growing 8.4%. HNH segment sales grew 8.9% driven by volume and pricing.
Net Earnings Jump 21.8% Nine months net earnings totaled $115.620M, marking a substantial 21.8% increase year-over-year comparison. Operating margin improved to 20.3%.
Operating Cash Flow Rises Cash provided by operating activities was $149.281M for nine months, increasing 15.1%. Investing activities used $27.475M.
Interest Expense Significantly Lower Nine months net interest expense decreased 39.3% to $8.319M due to lower outstanding borrowings under the 2022 Credit Agreement.

Risk Factors

Raw Material Input Costs Gross margin improvement partially offset by certain higher manufacturing input costs across nine months results comparison.
Foreign Currency Exchange Risk Exposure exists due to foreign subsidiaries' operations; currency fluctuations impact reported financial condition and results translation.
EU Anti-Dumping Duties Pending Provisional duties imposed on choline chloride imports from China; final measures expected by year-end 2025 impacting operations.
Litigation and Contingencies Exposure Ongoing involvement in various lawsuits, including Superfund site remediation liabilities at the Verona, Missouri facility.

Outlook

Focus on Productivity Enhancements Management plans to leverage existing technology capabilities to optimize productivity and performance, driving efficiencies moving forward.
Active Acquisition Candidate Pursuit Company actively pursuing additional acquisition candidates; may seek additional bank loans or access financial markets if needed.
Capital Structure Management Repurchase program remains active; intends to acquire shares based on cash flow assessment and market conditions.
New Accounting Standard Adoption Evaluating impact of recently issued ASU 2024-03 regarding comprehensive income expense disaggregation disclosures.

Peer Comparison

Revenue (TTM)

Sasol LimitedSSL
$28.48B
-6.5%
Celanese CorporationCE
$9.71B
-7.3%
Axalta Coating Systems Ltd.AXTA
$5.17B
-1.8%

Gross Margin (Latest Quarter)

Perimeter Solutions, Inc.PRM
58.3%
-4.5pp
Element Solutions IncESI
42.2%
+0.7pp
Balchem CorporationBCPC
35.7%
+0.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
AXTA$7.13B15.521.3%0.3%
ESI$6.17B25.79.4%32.2%
BCPC$5.07B34.312.1%9.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.7%
Moderate Growth
4Q Net Income CAGR
6.3%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 20, 2026
|
EPS:$1.29
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 21, 2025|
    Revenue: $267.56M+11.5%
    |
    EPS: $1.25+20.2%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 31, 2025|
    Revenue: $255.47M+9.1%
    |
    EPS: $1.18+19.2%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: Apr 24, 2025|
    Revenue: $250.52M+4.5%
    |
    EPS: $1.14+26.7%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 21, 2025|
    Revenue: $953.68M+3.4%
    |
    EPS: $3.97+17.5%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 25, 2024|
    Revenue: $239.94M+4.3%
    |
    EPS: $1.04+14.3%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 26, 2024|
    Revenue: $234.08M+1.2%
    |
    EPS: $0.99+5.3%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 3, 2024|
    Revenue: $239.66M+3.1%
    |
    EPS: $0.90+26.8%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 16, 2024|
    Revenue: $922.44M-2.1%
    |
    EPS: $3.38+2.7%
    Beat